November 13, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.11.003

Exploratory biomarker analysis of ribociclib plus letrozole in recurrent low-grade serous carcinoma: A GOG-3026 correlative study.

Listen to this summary

This exploratory translational study of the GOG-3026 trial asked which molecular and immune biomarkers (Ki-67, p16, pRB, ER/PR, genomic alterations, and immune phenotypes) are associated with response to ribociclib plus letrozole in recurrent low-grade serous ovarian carcinoma. In 24 archival tumors, lower Ki-67 was significantly associated with clinical benefit, and higher p16 showed a non-significant trend toward shorter progression-free survival, while no partial responders had an immune-hot phenotype. Because the analysis was exploratory and unadjusted for multiple testing, the authors conclude that these biomarkers warrant prospective validation before use in patient selection.

Kwong-Kwok Wong, Wei Deng, Yvonne T M Tsang, S John Weroha, Hye Sook Chon, Vivek Podder, Floor Backes, Eric Thomas, Meaghan Elizabeth Tenney, Shannon N Westin, Merry J Markham, Robert L Coleman, Thomas J Herzog, David M Gershenson, Brian M Slomovitz

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play